Research Use Only. Not for human or veterinary use. Not medical advice.

RC-TESA · Endocrine Signaling Research

RC-TESA vial (catalog image)

RC-TESA

Endocrine Signaling Research

Catalog code Research material Lyophilized format Variable presentations
Presentation

Vial sizes for laboratory supply, not a protocol.

Pricing
Sign in
Researcher pricing for approved accounts
In stock
As listed on the public catalog, Nov 17, 2026
Add to cart
0 25 50 75
83 of 100

Popularity

Very high

Public interest index

Trending down-14% vs prior 30 days

Research: Literature Activity 6/10 · Moderate (PubMed volume)

Data as of Nov 17, 2026 · Sources: Wikipedia pageviews, Reddit, X public mentions.

Measures online attention only. It is not a measure of quality, purity, efficacy, or safety.

Cover of the RC-TESA Research Booklet, Deep-Dive Series No. 2

Peptidea Deep Dive

RC-TESA Research Booklet
Deep-Dive Series · No. 2
PRB-TESA-001 Rev 1.1 · GHRH-analog peptide · research reference

A view-only research booklet for approved, signed-in researchers. It opens in the Research Document Library viewer on peptidea.net, so you can read it without leaving this site.

Sign in to read

Available in the Research Document Library after researcher approval.

Publications per year

Unique PubMed records grouped by publication year — a volume index, not a quality rating.

PubMed counts

Last updated Nov 17, 2026. 130 unique records for tesamorelin OR TH9507. 2026 is a partial year. Records begin in 2003 (130 unique in total). Source on PubMed

Key specifications

Catalog facts are taken from the live PEPTIDEA™ listing. Formula and molecular weight are from PubChem. Sequence is omitted here.

Catalog title
RC-TESA | Endocrine Signaling Research
Research focus
Endocrine Signaling Research
Also described as
Tesamorelin · TH9507
Format
Lyophilized research peptide
Catalog status
In stock (public listing)
Presentations
5, 10, 20, 30 mg vialsCatalog sizes, not a protocol
Molecular formula
C221H366N72O67SPubChem CID 16137828
Molecular weight
5,136PubChem average; exact mass 5,134.72
Receptor context
GHRH receptor (class B GPCR)Literature description; research context only
Sequence
Not reproduced hereSee primary literature / PubChem
Researcher access
Sign-in required to view pricing
PubMed records
130 uniqueQuery above, Nov 17, 2026

Catalog notes & use limitations

Research-catalog framing only. This section does not describe effects in people or study outcomes.

Catalog notes

Listed under Endocrine Signaling Research

RC-TESA appears in the PEPTIDEA™ collection with other endocrine- and growth-factor-focus materials, including RC-IPA, RC-IFL, and RC-CJCIPA.

GHRH-analog research context

Published literature describes tesamorelin (TH9507) as a synthetic analog of growth hormone-releasing hormone, GHRH(1–44). That is a mechanism-class description, not a use claim.

Investigational literature exists

The compound has been evaluated in clinical studies described in the public literature. This page does not summarize trial results, endpoints, or protocols.

Use limitations

Research use only

Not for human or veterinary use. Not a drug, not a cosmetic, and not medical advice. Not presented here as a treatment or weight-management product.

No outcome or dosing information

This page does not list administration amounts, schedules, or clinical results. Catalog vial sizes are presentations of the research material, not a protocol.

Confirm details from primary sources

Formula and molecular weight are cited from PubChem. Sequence is omitted. Read papers and the Deep Dive booklet for laboratory context — results stay in the original publications.

Specifications

Laboratory-catalog and public-chemistry details. Items without a cited source are marked.

Catalog titleRC-TESA | Endocrine Signaling Research
CategoryEndocrine Signaling Research (Endocrine & Growth Factor Signaling Research)
Associated namesTesamorelin; TH9507
FormatLyophilized research peptide
Public catalog statusIn stock (as of Nov 17, 2026)
Catalog presentations5, 10, 20, 30 mg vials — sizes of the research material, not a use protocol
Molecular formulaC221H366N72O67S (PubChem CID 16137828, retrieved Nov 17, 2026)
Molecular weight5,136 (PubChem average; exact mass 5,134.72)
InChIKeyQBEPNUQJQWDYKU-BMGKTWPMSA-N (PubChem)
Receptor contextDescribed in the literature as a synthetic analog of GHRH(1–44) acting at the GHRH receptor — research-class language only
SequenceNot reproduced on this page. See primary literature and the PubChem record.
PricingVisible after researcher sign-in
PubChem records for tesamorelin and the research code TH9507 resolve to CID 16137828. Sequence is omitted on this page.
Cover of the RC-TESA Research Booklet, Deep-Dive Series No. 2

Peptidea Deep Dive

RC-TESA Research Booklet
Deep-Dive Series · No. 2
PRB-TESA-001 Rev 1.1 · GHRH-analog peptide · research reference

A view-only research booklet for approved, signed-in researchers. It opens in the Research Document Library viewer on peptidea.net, so you can read it without leaving this site.

Sign in to read

Available in the Research Document Library after researcher approval.

Research literature

These are Peptidea-written summaries of selected publications, prepared so you can stay on peptidea.net. Each card describes what was studied — the research question, study type, and mechanism or setting. We do not restate results, endpoints, or protocols. Full papers remain with their publishers; a small PubMed source link is included only for citation.

Review

Spooner and Olin

Annals of Pharmacotherapy · 2012
Tesamorelin as a growth hormone-releasing factor analogue

This review identifies tesamorelin (also coded TH9507) as a growth hormone-releasing factor analogue and surveys the published clinical literature on the compound available through late 2011.

The paper discusses pharmacology, study design, and reported safety assessments in those studies. Numeric findings, administration amounts, and outcome results are not restated here.

Review

Dhillon

BioDrugs · 2011
Pharmacological properties of a synthetic GHRH analogue

This review describes tesamorelin as a synthetic analog of human growth hormone-releasing hormone and summarizes its reported pharmacological properties.

Clinical efficacy and tolerability sections in the paper are not reproduced on this page, and no administration amounts or endpoints are restated.

Analytical chemistry

Memdouh et al.

Drug Testing and Analysis · 2021
In-vitro metabolism and detection of synthetic GHRH analogues

This laboratory study examined in-vitro metabolism and detection of four larger synthetic GHRH analogues, including tesamorelin, in fortified urine samples.

The authors identified major in-vitro metabolites, prepared reference materials, and evaluated them as analytical standards. Experimental recovery figures and method cut-offs are not restated here.

Analytical chemistry

Uçaktürk and Nemutlu

Journal of Pharmaceutical and Biomedical Analysis · 2026
Nano-LC–Orbitrap mass spectrometry of GHRH and analogues

This paper reports a nano-liquid chromatography quadrupole/Orbitrap mass spectrometry method developed for screening and confirmation of GHRH and selected synthetic analogues, including tesamorelin, in urine.

The work focuses on analytical method design for peptides that are present at low concentrations and are prone to instability in that matrix. Validation statistics are not reproduced here.

Analytical chemistry

Colpaert et al.

Drug Testing and Analysis · 2026
LC-HRMS detection of tesamorelin and its metabolites

This analytical paper describes liquid chromatography–high-resolution tandem mass spectrometry methods aimed at detecting tesamorelin, a GHRH analogue, and related metabolites in human urine and serum.

The publication reports method development and metabolite identification in a post-administration detection study, including incubated-serum work. Quantitative findings and any administration details in the paper are not restated on this page.

Clinical trial protocol

Erlandson et al.

BMJ Open · 2026
Published protocol for a tesamorelin-and-exercise study

This paper is a clinical trial protocol. It describes the planned design of a study in which tesamorelin is to be evaluated, together with exercise, in a defined adult population.

Because this is a protocol, it sets out intended aims and assessments rather than completed results. Those planned endpoints are not reproduced here, and no findings are available to restate.

Original titles are omitted or neutralized when they use clinical-outcome wording. Counts and the optional source links use the query tesamorelin OR TH9507. Source on PubMed

Storage & handling

General laboratory-catalog guidance for layout purposes. Always follow the vial label and your institution’s written procedures.

  • Handle as a lyophilized research material intended for laboratory use only.
  • Store according to the conditions printed on the label and in any compound document provided to approved researchers.
  • Protect closed vials from moisture and unnecessary temperature swings.
  • If reconstitution is performed, use only the laboratory’s own written procedures. This page does not provide volumes, solvents, or working concentrations.
  • This material is not for human or veterinary use and is not medical advice.
No dosing, administration, or protocol instructions are included on this page.

Research Use Only. Not for human or veterinary use. Not medical advice. PEPTIDEA™ is a trademark of Grey Bug LLC.